Payment overview · 2025
General Payments
$124.46
7 reported records · 4 companies
Healthcare provider profile · identity verified
Luiz Nascimento, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMLET, NC · NPI 1245228261
Verified facts
What the public records show
CMS Open Payments records show Luiz Nascimento, MD received $124.46 in general payments during 2025 across 7 reported records.
GlaxoSmithKline, LLC. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.81 | 48.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.53 | 25.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.50 | 13.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.62 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.46 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.81 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 713 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 126 |
| Furosemide | Furosemide | 484 | 116 |
| Omeprazole | Omeprazole | 473 | 122 |
| Gabapentin | Gabapentin | 400 | 87 |
| Losartan Potassium | Losartan Potassium | 397 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 65 |
| Simvastatin | Simvastatin | 251 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 61 |
| Lisinopril | Lisinopril | 217 | 62 |
| Metformin Hcl | Metformin Hcl | 208 | 56 |
| Potassium Chloride | Potassium Chloride | 207 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 41 |
| Eliquis | Apixaban | 189 | 32 |
| Carvedilol | Carvedilol | 187 | 47 |
| Celecoxib | Celecoxib | 170 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 50 |
| Montelukast Sodium | Montelukast Sodium | 165 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 37 |
| Glimepiride | Glimepiride | 163 | 46 |
| Allopurinol | Allopurinol | 147 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 26 |
| Alprazolam | Alprazolam | 97 | 23 |
| Trazodone Hcl | Trazodone Hcl | 97 | 27 |
| Famotidine | Famotidine | 94 | 30 |
| Jardiance | Empagliflozin | 93 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 20 |
| Sertraline Hcl | Sertraline Hcl | 88 | 24 |
| Spironolactone | Spironolactone | 88 | 17 |
| Tramadol Hcl | Tramadol Hcl | 82 | 21 |
| Pregabalin | Pregabalin | 81 | 17 |
| Linzess | Linaclotide | 80 | 17 |
| Topiramate | Topiramate | 80 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 13 |
| Glipizide | Glipizide | 76 | 16 |
| Bupropion Hcl | Bupropion Hcl | 75 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Mirtazapine | Mirtazapine | 72 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 72 | 18 |
| Clonidine Hcl | Clonidine Hcl | 71 | 19 |
| Meloxicam | Meloxicam | 68 | 16 |
| Farxiga | Dapagliflozin Propanediol | 66 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 20 |
| Ozempic | Semaglutide | 58 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 14 |
| Atenolol | Atenolol | 55 | 13 |
| Lovastatin | Lovastatin | 55 | 16 |
| Trulicity | Dulaglutide | 55 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 12 |
| Valsartan | Valsartan | 54 | 12 |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 13 |
| Temazepam | Temazepam | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Calcium Acetate | Calcium Acetate | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 37 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 15 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Colchicine | Colchicine | 32 | 12 |
| Finasteride | Finasteride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Minoxidil | Minoxidil | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Estradiol | Estradiol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.46 · 7 records | GlaxoSmithKline, LLC. | ACCRUFER, AREXVY, BREZTRI, JARDIANCE, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error